Nostrum Laboratories Inc is recalling 7,071 bottles of Metformin Hydrochloride Extended-Release Tablets (750 mg), a prescription medication used to manage blood sugar in adults with type 2 diabetes. The recall was initiated because testing detected levels of N-Nitrosodimethylamine (NDMA) that exceed the acceptable daily intake limit set by the FDA. Consumers should continue taking their medication until they speak with a doctor or pharmacist, as the risk of stopping diabetes treatment suddenly may outweigh the risk of exposure to the impurity.
NDMA is classified as a probable human carcinogen, meaning it is a substance that could cause cancer with long-term exposure above safety limits. While no immediate injuries or illnesses have been reported from this specific batch, the presence of this impurity at elevated levels represents a potential long-term health risk.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.